Released May 9, 2024, after the close
10-Q filed May 9, 2024, 39 days after period end · 0000320017-24-000031
Q1 2023 · 10-Q
Revenue$0.00$0.00 — vs Q1 2022no prior Q4 2022 on file
Net Income-$5.40M-$5.40M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.65-$0.65 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$6,601,000N/M
Operating Cash Flow-$7,027,000N/M
Free Cash Flowderived-$7,027,000—
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — |
| Net Income | -$5.40M | -$6.19M | -$4.23M | -$8.06M |
| EPS Diluted | -$0.65 | -$0.77 | -$1.05 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR